Drugs / Anaprazole
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04476394 | Aug → Sep 2020 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04444011 | Jul → Sep 2020 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04471922 | Mar 2019 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04466748 | Sep → Dec 2015 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04463173 | Jun → Jul 2015 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04467060 | Aug 2014 → Jun 2015 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05604261 | Dec 2022 → Jul 2023 | dyskinesia of esophagus, gastroesophageal reflux disease, peptic esophagitis | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04503629 | Oct 2018 → May 2019 | duodenal ulcer | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT07606833 | Jun 2026 → Feb 2027 expected | Helicobacter pylori infectious disease | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07010107 | Jul 2025 → Apr 2026 overdue | peptic esophagitis | Xuanzhu Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04215653 | Jan 2020 → Feb 2021 | duodenal ulcer | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT07345689 | Jan → Oct 2026 expected | impaired renal function disease, liver disorder | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07330531 | Jan → Feb 2026 overdue | — | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anaprazole | “This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole...” NCT07606833 ↗12“Anaprazole Sodium Enteric-coated Tablets” NCT07330531 ↗ |
| Known as | Anaprazole Sodium | “Drug: Anaprazole Sodium enteric-coated tablet” NCT04466748 ↗3“Anaprazole Sodium Enteric-coated Tablets” NCT07330531 ↗ “Anaprazole Sodium enteric-coated tablet” NCT04471922 ↗ “Anaprazole Sodium 20mg” NCT04503629 ↗ |
| Action | Inhibit | “the novel PPI anaprazole” PMID 36580650 ↗ Dec 2022 |
| Modality | Other / unclassified | “Anaprazole, a novel PPI” PMID 34336894 ↗ Jul 2021 |
| Route | Oral | “administered orally once every 30-60 minutes before breakfast for 4 weeks” NCT04215653 ↗ |